Novo Nordisk’s combination GLP‑1/amylin candidate CagriSema delivered superior glycemic and weight‑loss outcomes versus semaglutide in a Phase 3 diabetes study, the company reported. In a trial of more than 2,700 people with type 2 diabetes, CagriSema showed greater reductions in HbA1c and numerically larger weight loss across multiple estimands, including up to ~14% in completer analyses versus ~10% with semaglutide. The study used semaglutide as an active comparator and tested two dose regimens; results strengthen Novo’s bid to extend its metabolic franchise and tighten competition among next‑generation combination injectables. While CagriSema met primary endpoints in diabetes, Novo has separately submitted obesity filings and will push for regulatory approvals across indications. Amylin agonists (cagrilintide) paired with GLP‑1s aim to broaden appetite and satiety effects; combined regimens may change treatment sequencing for diabetes and obesity. Payers and rival developers will evaluate durability, safety, and head‑to‑head efficacy versus Eli Lilly’s and other competitors’ assets. Key actors: Novo Nordisk, trial investigators, industry analysts; reporting from company releases and Dive/Reuters coverage.